ResearchSpace
metadata only
Repositioning FDA-approved drugs to identify potential mycobacterial FadD23 inhibitors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Identifying non-tuberculosis mycobacteria : is it time to introduce new molecular assays?#331681
- A Pan-TB Regimen Targeting Host and Microbe#888951
- Assessing Corynebacterium glutamicum as a surrogate of Mycobacterium tuberculosis for DNA gyrase inhibitor design.#398115
- Beyond bacilli: integrating the microbiome into the TB research agenda#4587
- S2 File - TBProfiler for automated calling of the association with drug resistance of variants in Mycobacterium tuberculosis#213582
Record · ID 309646
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive